Literature DB >> 31161941

Nebulized Tranexamic Acid Therapy for Hemoptysis Associated with Submassive Pulmonary Embolism.

Jayesh A Dhanani1,2,3, Jason Roberts1,2,4,5, Michael C Reade2,3,6.   

Abstract

Hemoptysis and pulmonary embolism (PE) are life-threatening pulmonary emergencies that, when present together, create a therapeutic conundrum. We present an illustrative case of a 65-year-old man with unprovoked submassive PE and moderate hemoptysis due to pulmonary infarction. Hemoptysis precluded systemic anticoagulation. Failing a conservative management strategy, we administered nebulized tranexamic acid. After four doses of nebulized tranexamic acid 500 mg, 6 hours apart, hemoptysis had ceased. Systemic anticoagulation with intravenous heparin was then successfully commenced 12 hours after the last episode of hemoptysis. The patient was weaned off high-flow nasal oxygen therapy over the course of the next 5 days with no hemoptysis recurrence. Noting the absence of trial evidence, but good pharmacological rationale and our positive experience, we suggest tranexamic acid is a useful noninvasive treatment option for the management of such conditions. Consent for this publication was obtained from the patient.

Entities:  

Keywords:  hemoptysis; nebulized; pulmonary embolism; tranexamic acid

Mesh:

Substances:

Year:  2019        PMID: 31161941     DOI: 10.1089/jamp.2019.1534

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  1 in total

1.  Inhaled Tranexamic Acid for Non-Massive Haemoptysis in a Rivaroxaban-Receiving Patient Not Responding to the Oral Form.

Authors:  Mugahid Eltahir; Mohamed Nabil Elshafei; Abdelnasser Elzouki
Journal:  Eur J Case Rep Intern Med       Date:  2020-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.